Last $72.97 USD
Change Today -1.89 / -2.52%
Volume 144.4K
GWPH On Other Exchanges
Symbol
Exchange
London
OTC US
NASDAQ GM
Frankfurt
NASDAQ GM
Stuttgart
As of 4:00 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

gw pharmaceuticals -adr (GWPH) Snapshot

Open
$73.73
Previous Close
$74.86
Day High
$75.39
Day Low
$72.52
52 Week High
07/1/14 - $111.46
52 Week Low
04/15/14 - $41.86
Market Cap
1.4B
Average Volume 10 Days
226.3K
EPS TTM
--
Shares Outstanding
19.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GW PHARMACEUTICALS -ADR (GWPH)

gw pharmaceuticals -adr (GWPH) Details

GW Pharmaceuticals plc, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. It operates in three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of multiple sclerosis symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.

265 Employees
Last Reported Date: 12/4/14
Founded in 1998

gw pharmaceuticals -adr (GWPH) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: 567.8K GBP
Founder, Executive Chairman and Chairman of N...
Total Annual Compensation: 696.1K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 389.8K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 421.8K GBP
Research & Development Director and Executive...
Total Annual Compensation: 475.3K GBP
Compensation as of Fiscal Year 2014.

gw pharmaceuticals -adr (GWPH) Key Developments

GW Pharmaceuticals and Otsuka Pharmaceutical Announce Results in First of Three Sativex(R) Phase 3 Cancer Pain Trials

GW Pharmaceuticals plc and Otsuka Pharmaceutical Development & Commercialization, Inc. reported the top-line results from the first of three Phase 3 trials for the investigational product Sativex in the treatment of pain in patients with advanced cancer who experience inadequate analgesia during optimized chronic opioid therapy. In this first trial, Sativex (as adjunctive treatment to optimized chronic opioid therapy) did not meet the primary endpoint of demonstrating a statistically significant difference from placebo. The primary efficacy measure of the study was a patient assessment of pain using a 0-to-10 Numeric Rating Scale (NRS) which was analysed using percent improvement from baseline as the primary analysis. In addition, improvement was also analysed using a cumulative proportion of responders analysis (CPRA), which analyses the full range of responses achieved across the entire patient population within a trial. In this trial, these analyses did not show a statistically significant difference between Sativex and placebo. The secondary endpoints followed the pattern of the primary endpoint. In this study, the United States was the single recruiting country. Although not statistically significant, the efficacy data from U.S. sites showed more positive trends than those in non-U.S. sites. This is consistent with data from the Phase 2b trial. The safety profile of Sativex in this Phase 3 trial was consistent with previous studies in this patient population. Overall, Sativex was well tolerated. The only adverse events reported at greater than 10% for the Sativex population were neoplasm progression (16% on Sativex vs 18% on placebo) and somnolence (12% on Sativex vs 4% on placebo). The other most frequently reported adverse event on Sativex was dizziness (8% on Sativex vs 5% on placebo). Otherwise, there was little difference in the adverse event pattern between Sativex and placebo. There were 38 (19%) withdrawals due to adverse events on Sativex compared with 29 (15%) on placebo.

GW Pharmaceuticals plc, Otsuka Pharmaceutical Development & Commercialization, Inc. - Special Call

To provides update on Epidiolex(R) Program in treatment resistant childhood epilepsies; and to discuss results in first of three Sativex(R) Phase 3 cancer pain trials

GW Pharmaceuticals plc(NasdaqGM:GWPH) added to NASDAQ Biotechnology Index

GW Pharmaceuticals plc will be added to the NASDAQ Biotechnology Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GWPH:US $72.97 USD -1.89

GWPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cannabis Science Inc $0.06 USD -0.0017
Medical Marijuana Inc $0.12 USD -0.0013
PharmaCyte Biotech Inc $0.11 USD -0.0053
View Industry Companies
 

Industry Analysis

GWPH

Industry Average

Valuation GWPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.7x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GW PHARMACEUTICALS -ADR, please visit www.gwpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.